|
Activity of tepotinib in hepatocellular carcinoma (HCC) with high-level MET amplification (METamp): Preclinical and clinical evidence. |
|
|
Consulting or Advisory Role - Bayer; Eisai; Ipsen; Merck Serono |
Speakers' Bureau - Bayer; Eisai |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb (Mexico); Eisai; Ipsen; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Eisai; MSD Oncology |
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai |
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
|
|
|
Employment - Merck Serono |
|
|
No Relationships to Disclose |